London Co. of Virginia Acquires 6,111 Shares of Haemonetics Co. (NYSE:HAE)

London Co. of Virginia raised its stake in Haemonetics Co. (NYSE:HAE - Free Report) by 2.2% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 281,738 shares of the medical instruments supplier's stock after buying an additional 6,111 shares during the period. London Co. of Virginia owned approximately 0.56% of Haemonetics worth $21,998,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. TD Waterhouse Canada Inc. purchased a new stake in shares of Haemonetics during the fourth quarter valued at $25,000. Covestor Ltd increased its stake in Haemonetics by 146.8% in the 4th quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier's stock worth $58,000 after purchasing an additional 439 shares in the last quarter. Whittier Trust Co. acquired a new stake in Haemonetics during the 4th quarter worth about $62,000. Parkside Financial Bank & Trust lifted its stake in Haemonetics by 25.6% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier's stock valued at $92,000 after buying an additional 240 shares in the last quarter. Finally, AlphaQuest LLC boosted its holdings in shares of Haemonetics by 36,520.0% in the fourth quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier's stock worth $143,000 after buying an additional 1,826 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

Haemonetics Stock Performance

NYSE:HAE traded up $0.71 during midday trading on Thursday, reaching $69.36. The stock had a trading volume of 599,483 shares, compared to its average volume of 698,146. The stock has a market capitalization of $3.48 billion, a P/E ratio of 27.31, a PEG ratio of 1.11 and a beta of 0.32. Haemonetics Co. has a 1-year low of $55.30 and a 1-year high of $96.14. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm's fifty day simple moving average is $62.84 and its 200-day simple moving average is $71.28.

Haemonetics (NYSE:HAE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. The business had revenue of $330.60 million during the quarter, compared to analysts' expectations of $329.38 million. Haemonetics had a return on equity of 23.66% and a net margin of 9.47%. The firm's revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.90 EPS. On average, equities research analysts forecast that Haemonetics Co. will post 4.55 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

HAE has been the subject of several research analyst reports. Bank of America downgraded shares of Haemonetics from a "neutral" rating to an "underperform" rating and reduced their price target for the company from $95.00 to $68.00 in a research report on Friday, February 7th. JMP Securities reduced their target price on Haemonetics from $125.00 to $100.00 and set a "market outperform" rating for the company in a report on Friday, February 7th. Barrington Research lowered their price target on Haemonetics from $108.00 to $95.00 and set an "outperform" rating on the stock in a report on Friday, February 7th. Raymond James reissued a "strong-buy" rating and set a $105.00 price target (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Finally, StockNews.com downgraded Haemonetics from a "buy" rating to a "hold" rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating, two have given a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Haemonetics presently has a consensus rating of "Moderate Buy" and an average price target of $97.89.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.